SCCB
MCID: BLD173
MIFTS: 44

Bladder Small Cell Carcinoma (SCCB)

Categories: Cancer diseases, Endocrine diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Bladder Small Cell Carcinoma

MalaCards integrated aliases for Bladder Small Cell Carcinoma:

Name: Bladder Small Cell Carcinoma 12
Small Cell Bladder Cancer 20 58 70
Poorly Differentiated Neuroendocrine Carcinoma of the Bladder 20 58
Small Cell Carcinoma of the Urinary Bladder 20 58
Small Cell Carcinoma of the Bladder 20 58
Small Cell Bladder Carcinoma 20 58
Sccb 20 58

Characteristics:

Orphanet epidemiological data:

58
small cell carcinoma of the bladder
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare urogenital diseases
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:0080902
Orphanet 58 ORPHA284400
UMLS 70 C2212594

Summaries for Bladder Small Cell Carcinoma

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 284400 Definition Small cell carcinoma of the bladder (SCCB) is a very rare, poorly differentiated neuroendocrine epithelial bladder tumor characterized clinically by hematuria and/or dysuria and a highly aggressive course. Epidemiology SCCB is extremely rare with an annual incidence of less than 1-9/1,000,000. Since 1980, fewer than 1,500 cases have been identified. The demographic profile of SCCB is similar to that of patients with bladder transitional cell carcinoma (TCC). The majority of patients are male, with a mean sex ratio of 5:1, and a range between 1:1 to 16:1. The vast majority of cases were reported in the Caucasian population. Clinical description Most knowledge on SCCB is based on retrospective investigations and on a few prospective studies. Mean age at diagnosis is 67 years (range 32 to 91 years). The clinical features of SCCB are similar to those of bladder TCC and reflect the presence of a tumoral mass. The main symptom is gross hematuria (63 to 88% of cases) with dysuria as the second most common symptom. Urinary obstruction, abdominal pain, urinary tract infection and weigh loss are occasionally present. SCCB often occurs with other types of carcinoma and is frequently found combined with other histological forms of bladder cancer : TCC, adenocarcinoma and squamous cell carcinoma. SCCB is generally believed to have a high metastatic potential. Rare cases of paraneoplastic syndromes such as ectopic ACTH secretion and hypercalcemia have also been reported. Etiology The etiology of the disease is unknown but a multipotent stem cell anomaly is thought to be a likely mechanism. A history of smoking is found in 65% to 79% of cases. Diagnostic methods Histology and immunohistochemistry show a tumor that is indistinguishable from small cell lung cancer (SCLC; see this term). Diagnosis of SCCB relies mainly on histopathological data obtained by cystoscopy and transurethral resection of the bladder tumor. Immunochemistry staining is useful in establishing the diagnosis. Light microscopy reveals packed cells having scant cytoplasm containing few organelles. Tumors are composed of nests of small round malignant cells with pyknotic round to oval nuclei and evenly dispersed ''salt and pepper chromatin ''. More than 95% of SCCB cases are diagnosed at muscle invasive stage T2 or later. Differential diagnosis The differential diagnosis includes direct invasion of the bladder by SCC of the prostate, metastatic SCC from another source, usually the lung, and primary lymphomas of the bladder. Management and treatment The staging system used is the TNM-staging of bladder transitional cell carcinoma. Treatment is extrapolated from that of SCLC. However, many patients with SCCB undergo radical resection which is rarely performed in SCLC. Patients with surgically resectable disease should be managed with multimodal therapy associating chemotherapy, surgery and/or radiotherapy. Neoadjuvant chemotherapy using 4 chemotherapy cycles followed by radical cystectomy is the most effective therapeutic sequence. Patients with unresectable disease should be managed with palliative chemotherapy based on neuroendocrine-type regimens comprising a platinum drug (cisplatin in fit patients). Prophylactic cranial irradiation should be considered in stages III/IV bladder SCC. Prognosis The prognosis of the disease is poor mainly in the case of pure small cell carcinoma.

MalaCards based summary : Bladder Small Cell Carcinoma, also known as small cell bladder cancer, is related to small cell carcinoma and neuroendocrine carcinoma. An important gene associated with Bladder Small Cell Carcinoma is ACP3 (Acid Phosphatase 3). Affiliated tissues include lung, prostate and pancreas, and related phenotypes are hematuria and bladder neoplasm

Disease Ontology : 12 A bladder carcinoma that is characterized as an undifferentiated neoplasm composed of primitive-appearing cells.

Related Diseases for Bladder Small Cell Carcinoma

Diseases related to Bladder Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 small cell carcinoma 30.3 PTPRC MUC1
2 neuroendocrine carcinoma 29.8 PTPRC MUC1
3 transitional cell carcinoma 10.6
4 rare tumor 10.4
5 bladder diverticulum 10.3
6 bladder urothelial carcinoma 10.3
7 in situ carcinoma 10.2
8 esophageal cancer 10.2
9 retinoblastoma 10.2
10 chondrosarcoma 10.2
11 osteogenic sarcoma 10.2
12 gastrointestinal stromal tumor 10.2
13 urinary tract infection 10.2
14 hydronephrosis 10.2
15 acute cystitis 10.2
16 chronic cystitis 10.2
17 papillary carcinoma 10.2
18 rhabdomyosarcoma 10.2
19 ureteral obstruction 10.2
20 urinary tract obstruction 10.2
21 splenomegaly 10.2
22 back pain 10.2
23 schistosoma mansoni infection, susceptibility/ 10.1
24 small cell cancer of the lung 10.1
25 stiff-person syndrome 10.1
26 suppression of tumorigenicity 12 10.1
27 dermatomyositis 10.1
28 bladder calculus 10.1
29 nephrotic syndrome 10.1
30 ureteral benign neoplasm 10.1
31 schistosomiasis 10.1
32 cystitis 10.1
33 neuroendocrine tumor 10.1
34 bladder squamous cell carcinoma 10.1
35 hypokalemia 10.1
36 prostate small cell carcinoma 10.1
37 amyloidosis 10.1
38 amyloidosis aa 10.1
39 paraneoplastic syndromes 10.1
40 bladder cancer 10.0
41 squamous cell carcinoma 10.0
42 adenocarcinoma 10.0
43 ureterocele 10.0
44 lung cancer 10.0
45 breast abscess 9.9
46 breast metaplastic carcinoma 9.9
47 primary cutaneous anaplastic large cell lymphoma 9.8 PTPRC MUC1
48 anaplastic large cell lymphoma 9.8 PTPRC MUC1
49 plasmablastic lymphoma 9.8 PTPRC MUC1
50 reticulum cell sarcoma 9.8 PTPRC MUC1

Graphical network of the top 20 diseases related to Bladder Small Cell Carcinoma:



Diseases related to Bladder Small Cell Carcinoma

Symptoms & Phenotypes for Bladder Small Cell Carcinoma

Human phenotypes related to Bladder Small Cell Carcinoma:

58 31 (show all 6)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hematuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0000790
2 bladder neoplasm 58 31 hallmark (90%) Very frequent (99-80%) HP:0009725
3 dysuria 58 31 frequent (33%) Frequent (79-30%) HP:0100518
4 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
5 recurrent urinary tract infections 58 31 occasional (7.5%) Occasional (29-5%) HP:0000010
6 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072

Drugs & Therapeutics for Bladder Small Cell Carcinoma

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Prophylactic Cranial Irradiation (PCI) for Patients With Small Cell Carcinoma of the Urothelium Active, not recruiting NCT00756639 Phase 2

Search NIH Clinical Center for Bladder Small Cell Carcinoma

Genetic Tests for Bladder Small Cell Carcinoma

Anatomical Context for Bladder Small Cell Carcinoma

MalaCards organs/tissues related to Bladder Small Cell Carcinoma:

40
Lung, Prostate, Pancreas

Publications for Bladder Small Cell Carcinoma

Articles related to Bladder Small Cell Carcinoma:

(show all 49)
# Title Authors PMID Year
1
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. 61
33358150 2020
2
Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report. 61
33082749 2020
3
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. 61
32521509 2020
4
A Rare Case of Small Cell Carcinoma of the Urinary Bladder. 61
32676247 2020
5
Evaluation of metastases to the pancreas with fine needle aspiration: A case series from a single centre with review of the literature. 61
31788890 2020
6
Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. 61
32061548 2020
7
Advanced small-cell bladder cancer into a ureterocele: A case report and literature review. 61
31440452 2019
8
Small cell bladder cancer: should we consider prophylactic cranial irradiation? 61
30521161 2019
9
Prognosis of early stage small cell bladder cancer is not always dismal. 61
31798978 2019
10
Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. 61
31191745 2019
11
Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. 61
30327311 2019
12
Quadruple primary urogenital cancers - A case report. 61
28858743 2017
13
Long term disease free survival with multimodal therapy in small cell bladder cancer. 61
27737712 2016
14
Microcytic carcinoma of the urinary bladder: Experience over 22 years. 61
26748843 2016
15
Diagnosis and treatment in primary bladder small cell carcinoma: Literature review. 61
27072176 2016
16
Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. 61
26679712 2016
17
[A CASE OF ADVANCED BLADDER NEUROENDOCRINE CARCINOMA (SMALL CELL CARCINOMA) SIGNIFICANTLY IMPROVED BY LOW DOSE OF ORAL TEGAFUR-URACIL]. 61
26717786 2015
18
POINT: Is Cystectomy Needed for Small-Cell Bladder Cancer? 61
26384800 2015
19
COUNTERPOINT: Is Cystectomy Needed for Small-Cell Bladder Cancer? 61
26384801 2015
20
Genitourinary small cell malignancies: prostate and bladder. 61
25675127 2015
21
The probability of involvement of human papillomavirus in the carcinogenesis of bladder small cell carcinoma, prostatic ductal adenocarcinoma, and penile squamous cell carcinoma: a case report. 61
25512116 2014
22
GATA3 expression in small cell carcinoma of bladder and prostate and its potential role in determining primary tumor origin. 61
24925221 2014
23
Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. 61
24036236 2014
24
Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. 61
23850495 2013
25
Clinical outcome of primary small cell carcinoma of the urinary bladder. 61
24009428 2013
26
[Small cell neuroendocrine carcinoma of the urinary bladder]. 61
24669571 2013
27
Small cell carcinoma of the urinary bladder: a rare, aggressive neuroendocrine malignancy. 61
23106592 2012
28
Small cell bladder cancer: biology and management. 61
23040258 2012
29
Primary metastatic neuroendocrine small cell bladder cancer: a case report and literature review. 61
22236613 2012
30
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. 61
21499238 2011
31
[Neuroendocrine small-cell bladder cancer: our experience]. 61
21308678 2010
32
Small cell carcinoma of the bladder in transplant recipients: a report of 2 cases. 61
20174486 2010
33
Outcome of recurrent and metastatic small cell carcinoma of the bladder. 61
19500382 2009
34
Autopsy case of primary small cell carcinoma of the urinary bladder: KIT and PDGFRA expression and mutations. 61
19351368 2009
35
Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. 61
17536302 2007
36
Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. 61
17289890 2007
37
Retraction notice to "CT features of bladder small cell carcinoma". 61
17176532 2006
38
[Primary small cell carcinoma of the bladder treated with partial cystectomy. Case report]. 61
16353777 2005
39
Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. 61
15855652 2005
40
[Infiltrative small cell carcinoma of the bladder. New case report: treatment with radical surgery and chemotherapy]. 61
15560278 2004
41
CT features of bladder small cell carcinoma. 61
15158225 2004
42
Small cell carcinoma of the bladder: a case report and a literature review. 61
12731451 2003
43
Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. 61
11173944 2001
44
Chromosomal imbalances in small cell carcinomas of the urinary bladder. 61
10547580 1999
45
Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. 61
9554367 1998
46
Transitional cell and uncommon urothelial carcinoma of renal pelvis/ureter and bladder: low incidence of human papilloma virus. 61
9198289 1997
47
[Small-cell carcinoma of the bladder: description of a case and review of the literature]. 61
8012427 1994
48
Primary urinary cytodiagnosis of a bladder small-cell carcinoma. 61
1851081 1991
49
Small cell carcinoma of the urinary bladder with hypercalcemia. 61
2994881 1985

Variations for Bladder Small Cell Carcinoma

Cosmic variations for Bladder Small Cell Carcinoma:

9 (show top 50) (show all 60418)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263080 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.946G>C p.E316Q 23:15822739-15822739 4
2 COSM88263088 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.965G>A p.R322K 23:15822758-15822758 4
3 COSM84510685 ZNF276 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.*420C>T p.? 16:89738666-89738666 4
4 COSM87276544 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4937C>T p.S1646F 16:72797745-72797745 4
5 COSM102043690 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8060C>T p.S2687L 16:72787474-72787474 4
6 COSM102034006 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.7070C>T p.T2357M 16:72788464-72788464 4
7 COSM149314765 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9829C>T p.P3277S 16:72788447-72788447 4
8 COSM87290232 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9829C>T p.P3277S 16:72788447-72788447 4
9 COSM102035771 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-6747G>C p.? 16:72957712-72957712 4
10 COSM102022922 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.2903T>A p.I968N 16:72797037-72797037 4
11 COSM87284313 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.6608G>A p.R2203H 16:72796074-72796074 4
12 COSM102041865 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-8627C>T p.? 16:72959592-72959592 4
13 COSM102042377 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5648G>T p.R1883I 16:72794292-72794292 4
14 COSM102026671 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5057C>G p.S1686* 16:72794883-72794883 4
15 COSM149282136 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8029G>A p.E2677K 16:72794653-72794653 4
16 COSM87286129 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2249A>G p.H750R 16:72957897-72957897 4
17 COSM102042654 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.-23-9030G>A p.? 16:72959995-72959995 4
18 COSM87296773 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.11065A>T p.K3689* 16:72787211-72787211 4
19 COSM149332078 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.11065A>T p.K3689* 16:72787211-72787211 4
20 COSM149268190 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5645T>A p.I1882N 16:72797037-72797037 4
21 COSM102034185 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5969A>G p.K1990R 16:72793971-72793971 4
22 COSM149297301 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9812C>T p.T3271M 16:72788464-72788464 4
23 COSM102042394 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2674G>C p.E892Q 16:72797266-72797266 4
24 COSM149318900 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5416G>C p.E1806Q 16:72797266-72797266 4
25 COSM149321603 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9964C>T p.Q3322* 16:72788312-72788312 4
26 COSM87291296 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.554C>T p.S185L 16:72959592-72959592 4
27 COSM87293009 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.10802C>T p.S3601L 16:72787474-72787474 4
28 COSM102023535 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.1853A>G p.N618S 16:72798087-72798087 4
29 COSM102047988 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-8556G>A p.? 16:72959521-72959521 4
30 COSM149317827 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.554C>T p.S185L 16:72959592-72959592 4
31 COSM87286411 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5886G>T p.E1962D 16:72796796-72796796 4
32 COSM87285294 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2434G>C p.E812Q 16:72957712-72957712 4
33 COSM102036900 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.2138C>T p.A713V 16:72797802-72797802 4
34 COSM87296470 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.883C>T p.R295C 16:72959263-72959263 4
35 COSM102025882 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.-23-6951C>T p.? 16:72957916-72957916 4
36 COSM149265910 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8849G>A p.R2950H 16:72793833-72793833 4
37 COSM149262739 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8376G>A p.M2792I 16:72794306-72794306 4
38 COSM87280212 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2458C>T p.R820C 16:72957688-72957688 4
39 COSM149304877 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.4880C>T p.A1627V 16:72797802-72797802 4
40 COSM149297628 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8711A>G p.K2904R 16:72793971-72793971 4
41 COSM102047690 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-8298C>T p.? 16:72959263-72959263 4
42 COSM149294302 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.9127A>G p.I3043V 16:72793555-72793555 4
43 COSM87271951 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8376G>A p.M2792I 16:72794306-72794306 4
44 COSM87291784 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7576C>T p.Q2526* 16:72795106-72795106 4
45 COSM102042385 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4834C>T p.Q1612* 16:72795106-72795106 4
46 COSM149262746 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.808G>A p.D270N 16:72959338-72959338 4
47 COSM87274117 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.308G>A p.R103H 16:72959838-72959838 4
48 COSM87283980 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9812C>T p.T3271M 16:72788464-72788464 4
49 COSM149318895 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7576C>T p.Q2526* 16:72795106-72795106 4
50 COSM102025196 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2195C>T p.S732F 16:72797745-72797745 4

Expression for Bladder Small Cell Carcinoma

Search GEO for disease gene expression data for Bladder Small Cell Carcinoma.

Pathways for Bladder Small Cell Carcinoma

GO Terms for Bladder Small Cell Carcinoma

Cellular components related to Bladder Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 8.8 PTPRC MUC1 ACP3

Biological processes related to Bladder Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dephosphorylation GO:0016311 8.96 PTPRC ACP3
2 peptidyl-tyrosine dephosphorylation GO:0035335 8.62 PTPRC ACP3

Molecular functions related to Bladder Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatase activity GO:0016791 8.96 PTPRC ACP3
2 protein tyrosine phosphatase activity GO:0004725 8.62 PTPRC ACP3

Sources for Bladder Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....